Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3477-3483

  Holmes McNary, Minnie ^a   Baldwin Jr , Albert S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RESVERATROL;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; ENZYME INHIBITION; GENE EXPRESSION; GRAPE; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; ONCOGENE H RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; CELL LINE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; I-KAPPA B KINASE; LUCIFERASES; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STILBENES; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 0034234254     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science (Washington DC), 275: 218-220, 1997.
2. Soleas, G. J., Diamandis, K. P., and Goldberg, D. M. Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal., 11: 287-313, 1997.
3. Richard, J. L. Coronary risk factors. The French paradox. Arch. Mal Coeur Vaiss., 80: 17-21, 1987.
4. Renaud, S., and de Lorgeril, M. The French paradox: dietary factors and cigarette smoking-related health risks. Ann. N. Y. Acad. Sci., 686: 299-309, 1993.
5. Gronbaek, M., Deis, A., Sorensen, T. I., Becker, U., Schnohr, P., and Jensen, G. Mortality associated with moderate intakes of wine, beer, or spirits. Br. Med. J., 310: 1165-1169, 1995.
6. Gehm, B. D., McAndrews, J. M., Chien, P. Y., and Jameson, J. L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA, 94: 14138-14143, 1997.
7. Lu, R., and Serrero, G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol., 179: 297-304, 1999.
8. Basly, J-P., Marre-Fournier, F., Le Bail, J-C., Habrioux, G., and Chulia, A. J. Estrogenic/antiestrogenic and scavenging properties of (E)-and (Z)-resveratrol. Life Sci., 66: 769-777, 2000.
9. Goldberg, D. M. More on antioxidant activity of resveratrol in red wine. Clin. Chem., 42: 113-114, 1996.
10. Kanada, N., Seki, S., Inoue, M. and Kuroki, T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology, 27: 1265-1274, 1998.
11. Waffo Teguo, P., Fauconneau, B., Deffieux, G., Huguet, F., Vercauteren, J., and Merillon, J. M. Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from Vitis vinifera cell cultures. J. Nat. Prod., 61: 655-657, 1498.
12. Ray, P. S., Maulik, G., Cordis, G. A., Bertelli, A. A., Bertelli, A., and Das, D. K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radical Biol. Med., 27: 160-169, 1999.
13. Mgbonyebi, O. P., Russo, J., and Russo, I. H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol., 12: 865-869, 1998.
14. Carbo, N., Costelli, P., Baccino, F. M., Lopez-Soriano, F. J., and Argiles, J. M. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem. Biophys. Res. Commun., 254: 739-743, 1999.
15. Fontecave, M., Lepoivre, M., Elleingand, H., Gerez, C., and Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett., 421: 277-279, 1998.
16. ElAttar, T. M., and Virji, A. S. Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs, 10: 187-193, 1999.
17. Tsai, S. H., Lin-Shiau, S. Y., and Lin, J. K. Suppression of nitric oxide synthase and the down-regulation of the activation of NF-κB in macrophages by resveratrol. Br. J. Pharmacol., 126: 673-680, 1999.
18. Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., and Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 273: 21875-21882, 1998.
19. Barnes, P. J., and Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med., 336: 1066-1071, 1997.
20. Brand, K., Page, S., Walli, A. K., Neumeier, D., and Baeuerle, P. A. Role of nuclear factor-κB in atherogenesis. Exp. Physiol., 82: 297-304, 1997.
21. Jobin, C., Panja, A., Hellerbrand, C., Iimuro, Y., Didonato, J., Brenner, D. A., and Sartor, R. B. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor κB super-repressor in human intestinal epithelial cells. J. Immunol., 160: 410-418, 1998.
22. Miagkov, A. V., Kovalenko, D. V., Brown, C. E., Didsbury, J. R., Cogswell, J. P., Stimpson, S. A., Baldwin, A. S., and Makarov, S. S. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA, 95: 13859-13864, 1998.
23. Mayo, M. W., Wang, C. Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., and Baldwin, A. S., Jr. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (Washington DC), 278: 1812-1815, 1997.
24. Hargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D, Grinstein, E., Greiner, A., Scheidereit, C., and Dorken, B. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest., 100: 2961-2969, 1997.
25. Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., and Sonenshein, G. E. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest., 100: 2952-2960, 1997.
26. Reuther, J. Y., Reuther, G. W., Cortez, D., Pendcrgast, A. M., and Baldwin, A. S., Jr. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev., 12: 968-981, 1998.
27. Krappmann, D., Emmerich, F., Kordes, U., Scharschmidt, E., Dorken, B., and Scheidereit, C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene, 18: 943-953, 1999.
28. Baldwin, A. S., Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol., 14: 649-683, 1996.
29. Verma, I. M., and Stevenson, J. IκB kinase: beginning, not the end. Proc. Natl. Acad. Sci. USA, 94: 11758-11760, 1997.
30. Maniatis, T. Catalysis by a multiprotein IκB kinase complex. Science (Washington DC), 278: 818-819, 1997.
31. Ghosh, S., May, M. J., and Kopp, E. B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 16: 225-260, 1998.
32. Finco, T. S., Westwick, J. K., Morris, J. L., Beg, A. A., Der, C. J., and Baldwin, A. S., Jr. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem., 272: 24113-24116, 1997.
33. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., and Sledge, G. W., Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol., 17: 3629-3639, 1997.
34. Sasano, H., Frost, A. R., Saitoh, R., Taniyama, Y., Nagura, H., Matsunaga, G., Takehana, K., Kimura, M., and Silverberg, S. G. Immunolocalization of cyclins D and E and cyclin-dependent kinase (cdk) 2 and 4 in human breast carcinoma. Anticancer Res., 17: 3685-3690, 1997.
35. Hedberg, Y., Davoodi, E., Roos, G., Ljungberg, B., and Landberg, G. Cydin-D1 expression in human renal-cell carcinoma. Int. J. Cancer, 84: 268-272, 1999.
36. Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., and Baldwin, A. S., Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell Biol., 19: 5785-5799, 1999.
37. 0/G1-to-S-phase transition. Mol. Cell. Biol., 19: 2690-2698, 1999.
38. Xie, Q. W., Kashiwahara, Y., and Nathan, C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J. Biol. Chem., 269: 4705-4708, 1994.
39. Yamamoto, K., Arakawa, T., Ueda, N., and Yamamoto, S. Transcriptional roles of nuclear factor κB and nuclear factor interleukin-6 in tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem., 270: 31315-31350, 1995.
40. Finco, T. S., Beg, A. A., and Baldwin, A. S., Jr. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. USA, 91: 11884-11888, 1994.
41. Cogswell, P. C., Mayo, M. W., and Baldwin, A. S., Jr. Involvement of Egr-1/RelA synergy in distinguishing T cell activation from tumor necrosis factor-α-induced NF-κBI transcription. J. Exp. Med., 185: 491-497, 1997.
42. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
43. Norris, J. L., and Baldwin, A. S., Jr. Oncogenic Ras enhances BF-kB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J. Biol. Chem., 274: 13841-13846, 1999.
44. Boring, L., Gosling, J., Cleary, M., and Charo, I. F. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (Lond.), 394: 894-897, 1998.
45. DiDonato, J. A., Hayakawa, M., Rothwarl, D. M., Zandi, E., and Karin, M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature (Lond.), 388: 548-554, 1997.
46. Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J., Young, D. B., Barbosa, M., Mann, M., Manning, A., and Rao, A. IKK-1 and IKK-2: cytokine-activaled IκB kinases essential for NF-κB activation. Science (Washington DC), 278: 860-866, 1997.
47. Woronicz, J. D., Gao, X., Cao, Z., Rothe, M., and Goeddel, D. V. IκB kinase-β. NF-κB activation and complex formation with IκB kinase-α and NIK. Science (Washington DC), 278: 866-869, 1997.
48. Regnier, C. H., Song, H. Y., Goeddel, D. V., Cao, Z., and Rothe, M. Identification and charaerterization of an IκB kinase. Cell. 90: 373-383, 1997.
49. Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. The IκB kinase complex (IKK) contains two kinase subunits. IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell. 91: 243-252, 1997.
50. Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y., and Ballard, D. W. Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol. Cell. Biol., 15: 2809-2818, 1995.
51. Brown, K., Gerstenberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. Control of IκBα proteolysis by site-specific, signal-induced phosphorylation. Science (Washington DC), 267: 1485-1491, 1995.
52. Traenckner, E. B., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., and Baeuerle, P. A. Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J., 14: 2876-2883, 1995.
53. Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev., 9: 1586-1597, 1995.
54. Li, N., and Karin, M. Is NF-κB the sensor of oxidative stress? FASEB J., 13: 1137-1143, 1999.
55. Finco, T. S., and Baldwin, A. S. Mechanistic aspects of NF-κB regulation: the emerging role of phosphorylation and proteolysis. Immunity, 3: 263-272, 1995.
56. Block, G., Patterson, B., and Subar, A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer, 18: 1-29, 1992.
57. Willett, W. C. Diet and health: what should we eat? Science (Washington DC), 264: 532-537, 1994.
58. Hu, F. B., Stampfer, M. J., Manson, J. E., Rimm, E., Colditz, G. A., Rosner, B. A., Hennekens, C. H., and Willett, W. C. Dietary fat intake and the risk of coronary heart disease in women. N. Engl. J. Med., 117: 1491-1499, 1997.
59. Li, D., Wang, M., Paul, G. P., Pilot, H. C., and Dragan, Y. Dietary oat lipids-induced novel DNA modifications and suppression of altered hepatic foci formation. Nutr. Cancer. 33: 40-45, 1999.
60. Constant, J. Alcohol, ischemic heart disease, and the French paradox. Coron. Artery Dis., 8: 645-649, 1997.
61. Kopp, P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox"? Eur. J. Endocrinol., 138: 619-620, 1998.
62. Wattenberg, L. W. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J. Natl. Cancer Inst., 58: 395-398, 1977.
63. Clinton, S. K., and Giovannucci, E. Diet, nutrition, and prostate cancer. Annu. Rev. Nutr., 18: 413-440, 1998.
64. Lee, F. S., Hagler, J., Chen, Z. J., and Maniatis, T. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell, 88: 213-222, 1997.
65. Karin, M., and Delhase, M. JNK or IKK, AP-1 or NF-κB, which are the targets for MEK kinase 1 action? Proc. Natl. Acad. Sci. USA, 95: 9067-9069, 1998.
66. Ling, L., Cao, Z., and Goeddel, D. V. NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA, 95: 3792-3797, 1998.
67. Nakano, H., Shindo, M., Sakon, S., Nishinaka, S., Mihara, M., Yagita, H., and Okumura, K. Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc. Natl. Acad. Sci. USA, 95: 3537-3542, 1998.
68. Dong, G., Chen, Z., Kato, T., and Van Waes, C. The host environment promotes the constitutive activation of nuclear factor-κB and proinflammalory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res., 59: 3495-3504, 1999.
69. Gilmore, T. D., Koedood, M., Piffat, K. A., and White, D. W. Rel/NF-κB/IκB proteins and cancer. Oncogene, 13: 1367-1378, 1996.
70. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science (Washington DC), 274: 787-789, 1996.
71. Kopp, E., and Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science (Washington DC), 265: 956-959, 1994.
72. Yin, M. J., Yamamoto, Y., and Gaynor, R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature (Lond.), 396: 77-80, 1998.
73. Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A., and Baldwin, A. S., Jr. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol. Cell. Biol., 15: 943-953, 1995.
74. Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., and Baldwin, A. S., Jr. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science (Washington DC), 270: 283-286, 1995.
75. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., and Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science (Washington DC), 270: 286-290, 1995.
76. Caldenhoven, E., Liden, J., Wissink, S., Van de Stolpe, A., Raaijmakers, J., Koenderman, L., Okret, S., Gustafsson, J. A., and Van der Saag, P. T. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol., 9: 401-412, 1995.